Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Common Stock Issued
Cash raised by issuing new shares.
Aurora Cannabis Inc.NASDAQ: ACB
Common Stock Issued · Q4 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q4 FY2026 common stock issued of CA$9.35M rose 1363.6% year over year, ahead of the +1112.0% change in trailing-twelve-month common stock issued. Sequentially, it rose 1580.4% from the prior quarter. Over 3 fiscal years it compounded at -48.6% a year.
Context
- Common stock issued amounted to 3.1% of revenue in FY2026, up 2.9 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1363.6% holds above the trailing-twelve-month pace of +1112.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
CAD · from the cash flow
- Latest · FY2026
- 9.94M CAD
- Year-over-year change
- +1112.3%
- 4-year CAGR
- -59.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 9.94M | +1112.3% |
| FY2025 | 2025-03-31 | 820K | -97.8% |
| FY2024 | 2024-03-31 | 37.92M | -48.2% |
| FY2023 | 2023-03-31 | 73.19M | -79.1% |
| FY2022 | 2022-06-30 | 350.19M | — |
Common Stock Issued vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1112.0% is the 2nd highest of 10, against a peer median of -27.3%.
- Common stock issued amounts to 3.2% of revenue for ACB, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$408.55M CAD | +6.0% | +609.2% | 130.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $143.89M USD | +420.9% | +640.5% | 1394.8% |
| LTM Mar 2026 | $58.03M USD | -22.6% | — | 693.6% | |
| LTM Mar 2026 | $41.66M USD | -27.3% | +223.2% | 107.7% | |
| LTM Mar 2026 | CA$9.94M CAD | +1112.0% | -48.6% | 3.2% | |
| LTM Mar 2026 | $9.27M USD | +74091.0% | — | 4.2% | |
| LTM Apr 2026 | CA$432.57K CAD | -88.3% | -69.4% | 0.1% | |
| LTM Mar 2026 | $210K USD | -78.1% | -71.7% | 0.1% | |
| LTM Mar 2026 | $144K USD | -99.1% | -21.7% | 0.3% | |
| LTM Mar 2026 | CA$42.2K CAD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $8K USD | — | — | 0.0% | |
| Peer median (excluding ACB) | — | -27.3% | +100.8% | 2.3% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (1.72B) | (265.33M) | (57.08M) | 15.76M | (58.77M) |
| Depreciation & Amortization | 93.66M | 43.57M | 32.78M | 22.55M | 14.23M |
| Deferred Income Tax | (2.19M) | (18.4M) | (1.67M) | (3.19M) | 55.14K |
| Stock-Based Compensation | 13.76M | 16.89M | 12.72M | 11.52M | 7.29M |
| Change in Working Capital | 52.65M | (25.12M) | (15.54M) | 10.21M | (9.24M) |
| Accounts Receivables | 18.34M | 5.53M | (4.5M) | 5.24M | (8.17M) |
| Inventory | 21.07M | 49.03M | 3.87M | (15.05M) | 65.93M |
| Accounts Payables | 6.77M | (8.06M) | (15.7M) | 14.91M | (8.06M) |
| Other Working Capital | 6.48M | (71.61M) | 790K | 5.11M | (58.93M) |
| Other Non-Cash Items | 1.45B | 190.11M | (39.71M) | (40.85M) | 40.18M |
| Operating Cash Flow | (110.27M) | (115.82M) | (68.51M) | 16.01M | (13.55M) |
| Capital Expenditures | (32.21M) | (12.13M) | (16.83M) | (18.86M) | (22.6M) |
| Acquisitions (Net) | (23.42M) | (18.54M) | (5.55M) | 0 | 1.1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | (52.35M) |
| Sales of Investments | 0 | 3.36M | 4.99M | 5.49M | 0 |
| Other Investing Activities | 19.46M | 16K | 14.02M | (956K) | 235.61K |
| Investing Cash Flow | (36.17M) | (27.29M) | (3.36M) | (14.33M) | (73.62M) |
| Debt Repayment | (170.83M) | — | (85.37M) | (805K) | (5.02M) |
| Common Stock Issued | 350.19M | 73.19M | 37.92M | 820K | 9.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (31.58M) | (95.21M) | (475K) | (131K) | (154.4K) |
| Financing Cash Flow | 147.78M | (56.48M) | (47.92M) | (116K) | 9.79M |
| Effect of Forex Changes | 15.01M | 15.54M | 297K | 264K | 10.56M |
| Net Change in Cash | 16.35M | (140.01M) | (119.5M) | 1.83M | (66.81M) |
| Free Cash Flow | (142.48M) | (127.95M) | (85.34M) | (2.85M) | (36.15M) |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.